NCT05646524View on ClinicalTrials.gov

Study of Efficacy and Safety of NM8074 in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 30, 2026

Primary Completion Date

August 31, 2027

Study Completion Date

September 30, 2028

Conditions
Paroxysmal Nocturnal Hemoglobinuria
Interventions
DRUG

NM8074

NM8074 will be administered as an intravenous infusion. Doses will be administered over a treatment period of 13 weeks.

Sponsors
All Listed Sponsors
lead

NovelMed Therapeutics

INDUSTRY